Zeolite Research

This review examines the chemistry and diverse medical applications of PMA-zeolite, a well-characterized clinoptilolite variant. The authors highlight that while exact biological mechanisms are not fully understood, evidence points to antioxidative, immunomodulatory, and detoxifying effects partly mediated through the release of bioavailable silica.

Clinical applications showing the most promise include supportive therapy for inflammatory conditions, beneficial effects in osteoporosis management, and assistance during chemotherapy. The review emphasizes that geographical origin and manufacturing processes create significant physicochemical variations that affect biological activity and safety.

The authors conclude that standardized, well-characterized materials like PMA-zeolite are essential for establishing reliable clinical applications, and call for further investigation of this material as a complementary therapeutic agent.

This non-interventional (observational) study evaluated the use of PMA-zeolite (panaceo med acute, a purified clinoptilolite product) in 82 patients diagnosed with irritable bowel syndrome (IBS) across all subtypes — IBS-D (diarrhea-predominant), IBS-C (constipation-predominant), and IBS-M (mixed). Patients took zeolite for 12 weeks and were assessed using the Bristol Stool Scale and IBS-SSS (Symptom Severity Score).

Across all three IBS subtypes, stool consistency improved significantly toward the normal range on the Bristol Stool Scale. IBS-D patients saw their scores decrease (firmer stools), while IBS-C patients saw scores increase (softer stools), and IBS-M patients stabilized. Overall symptom severity as measured by IBS-SSS also improved substantially, with the mean score dropping from moderate-severe to mild categories.

As a non-interventional study without a placebo control, the evidence is limited by potential placebo effects and reporting bias. However, the results are consistent with findings from controlled trials of clinoptilolite in IBS and suggest broad applicability across IBS subtypes, supporting its role as a complementary gut health intervention.

This study evaluated the effects of defined PMA-zeolite (clinoptilolite) supplementation on mineral and contaminant blood levels across three controlled clinical trials with different durations: 28 days, 12 weeks, and 4 years.

Results showed that nickel and aluminum levels significantly decreased after 4-year supplementation (p < 0.001), and arsenic decreased significantly after 12 weeks. Lead levels initially rose but normalized with continued use. However, copper, sodium, and calcium dropped below reference values in osteoporosis patients on long-term supplementation, raising concerns about essential mineral depletion.

The authors recommend monitoring mineral balance after one year in patients receiving zeolite supplementation, particularly those with osteoporosis. No aluminum or lead leakage from the zeolite itself was detected one hour post-intake in the short-term trial.

This randomized, double-blind, placebo-controlled trial investigated the efficacy and safety of purified clinoptilolite-tuff (zeolite) in 41 patients with diarrhea-predominant irritable bowel syndrome (IBS-D). Participants received either 3 g/day of clinoptilolite or placebo for 12 weeks, with a 4-week follow-up period.

The zeolite group showed statistically significant improvements in stool consistency as measured by the Bristol Stool Scale, with a meaningful reduction in the number of days per week with loose or watery stools compared to placebo. The treatment was well-tolerated with no significant adverse effects reported, confirming the favorable safety profile of purified clinoptilolite.

This is one of the few rigorous RCTs specifically examining zeolite for IBS-D, and the positive results provide moderate-quality evidence supporting clinoptilolite as a safe, non-pharmacological option for managing diarrhea-predominant IBS symptoms. The mechanism is thought to involve zeolite's ion-exchange and adsorptive properties in the gut lumen, helping to normalize intestinal fluid balance.

The ZeOxaNMulti trial was a randomized, double-blind, placebo-controlled study examining whether oral PMA-zeolite (panaceo med acute) could prevent or reduce chemotherapy-induced side effects in cancer patients receiving oxaliplatin-based regimens. Oxaliplatin is well known to cause dose-limiting peripheral neuropathy alongside other gastrointestinal and hematological side effects.

Patients in the zeolite group experienced significantly lower rates and severity of peripheral neuropathy compared to the placebo group. Additional benefits were observed in reduced gastrointestinal side effects including nausea, diarrhea, and mucositis. The zeolite supplementation did not interfere with the antitumor efficacy of the chemotherapy regimen, an important safety consideration.

These findings suggest that clinoptilolite-zeolite may serve as a supportive care agent during chemotherapy by reducing toxic side effects through its adsorptive and detoxification properties. The study adds to the growing body of evidence that zeolite supplementation can improve quality of life in clinical settings involving significant toxin exposure, while maintaining a favorable safety profile.

This review examines the therapeutic potential of naturally occurring zeolite clinoptilolite (ZC) and its modified forms, including tribomechanically activated (TMAZ) and micronized variants. The authors survey evidence from both preclinical and clinical studies.

Key findings include that ZC can reduce ammonia concentrations, improve intestinal barrier integrity, and support immune function through effects on intestinal lymphoid tissue. Metal ions within the zeolite structure may serve as cofactors for antioxidant enzyme activation, and modified forms like TMAZ and PMA-ZC showed enhanced protection against oxidative stress compared to untreated controls.

Despite extensive use in industrial and supplement applications, the review emphasizes that many underlying mechanisms remain unclear, particularly in human systems. The authors call for expanded preclinical and clinical research to validate the therapeutic claims.

This comprehensive review examines the safety and medical applications of clinoptilolite zeolite, the form most commonly used in supplements.

While in vitro and animal studies show zeolite can bind heavy metals and certain toxins, human clinical evidence remains limited. The review notes concerns about potential binding of essential minerals and the need for more rigorous human trials.